Clinical experience with imipenem/cilastatin: analysis of a multicenter study.
For 256 of the 338 patients in a multicenter study treated with imipenem/cilastatin (mean daily dosage, 1.6 g per day; mean duration of treatment, 8.5 days) for a variety of infections, 286 infections were microbiologically proven. Clinical cure was achieved in 216 of these infections and improvement, in 18. Ninety-eight of these infections were classified as severe or moderately severe. The infecting pathogen was eradicated in 79% of the infections. Therapy with imipenem/cilastatin was discontinued in 10(3%) of 338 patients because of adverse gastrointestinal effects. Pathologic laboratory parameters were reported for 28 patients (8%); in only one patient with thrombocytopenia was therapy discontinued. Renal tolerance of imipenem/cilastatin was good, and no nephrotoxicity was observed. From the susceptibility tests available for 452 bacterial strains, a susceptibility breakpoint of less than or equal to 8 micrograms/ml is recommended.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D015377:Cilastatin; D002986:Clinical Trials as Topic; D003521:Cyclopropanes / Q000008:administration & dosage* / Q000009:adverse effects; D004064:Digestive System / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015378:Imipenem; D007668:Kidney / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D013845:Thienamycins / Q000008:administration & dosage* / Q000009:adverse effects
D003521:Cyclopropanes; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem